JP2014508128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508128A5 JP2014508128A5 JP2013546401A JP2013546401A JP2014508128A5 JP 2014508128 A5 JP2014508128 A5 JP 2014508128A5 JP 2013546401 A JP2013546401 A JP 2013546401A JP 2013546401 A JP2013546401 A JP 2013546401A JP 2014508128 A5 JP2014508128 A5 JP 2014508128A5
- Authority
- JP
- Japan
- Prior art keywords
- bicyclo
- octan
- carboxamide
- methyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 alkyl carbamate Chemical compound 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000015114 central nervous system disease Diseases 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 4
- 125000004306 triazinyl group Chemical group 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 230000001149 cognitive effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000000626 neurodegenerative effect Effects 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims 7
- 208000020401 Depressive disease Diseases 0.000 claims 5
- 208000024714 major depressive disease Diseases 0.000 claims 4
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 4
- QWEWLLNSJDTOKH-UHFFFAOYSA-N 1,3-thiazole-2-carboxamide Chemical compound NC(=O)C1=NC=CS1 QWEWLLNSJDTOKH-UHFFFAOYSA-N 0.000 claims 3
- PABVQLMXDGVYBS-UHFFFAOYSA-N 6-methylpyrazine-2-carboxamide Chemical compound CC1=CN=CC(C(N)=O)=N1 PABVQLMXDGVYBS-UHFFFAOYSA-N 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- JVNOQZOWRVXECJ-VQTJNVASSA-N 5-fluoro-n-[(1r,5s)-5-(pyridine-2-carbonylamino)-1-bicyclo[3.2.1]octanyl]pyridine-2-carboxamide Chemical compound N1=CC(F)=CC=C1C(=O)N[C@@]1(CCC2)C[C@@]2(NC(=O)C=2N=CC=CC=2)CC1 JVNOQZOWRVXECJ-VQTJNVASSA-N 0.000 claims 2
- BCCUXBGEPLKSEX-UHFFFAOYSA-N 5-methylpyridine-3-carboxamide Chemical compound CC1=CN=CC(C(N)=O)=C1 BCCUXBGEPLKSEX-UHFFFAOYSA-N 0.000 claims 2
- DESCPWKNFVHGHO-VQTJNVASSA-N 6-fluoro-n-[(1r,5s)-5-(pyridine-2-carbonylamino)-1-bicyclo[3.2.1]octanyl]pyridine-2-carboxamide Chemical compound FC1=CC=CC(C(=O)N[C@@]23C[C@@](CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 DESCPWKNFVHGHO-VQTJNVASSA-N 0.000 claims 2
- OCVKYJFCWLTEPM-RTWAWAEBSA-N 6-methyl-n-[(1r,5s)-1-(pyridine-2-carbonylamino)-5-bicyclo[3.2.1]octanyl]pyridine-2-carboxamide Chemical compound CC1=CC=CC(C(=O)N[C@]23C[C@](CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 OCVKYJFCWLTEPM-RTWAWAEBSA-N 0.000 claims 2
- OCVKYJFCWLTEPM-LEWJYISDSA-N 6-methyl-n-[(1s,5r)-1-(pyridine-2-carbonylamino)-5-bicyclo[3.2.1]octanyl]pyridine-2-carboxamide Chemical compound CC1=CC=CC(C(=O)N[C@@]23C[C@@](CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 OCVKYJFCWLTEPM-LEWJYISDSA-N 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- 201000003104 endogenous depression Diseases 0.000 claims 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 2
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 claims 2
- XHWVYZXQFZPTLE-VQTJNVASSA-N 2-methyl-n-[(1r,5s)-5-(pyridine-2-carbonylamino)-1-bicyclo[3.2.1]octanyl]pyrimidine-4-carboxamide Chemical compound CC1=NC=CC(C(=O)N[C@@]23C[C@@](CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 XHWVYZXQFZPTLE-VQTJNVASSA-N 0.000 claims 1
- OZSDTKZLTREFCH-UHFFFAOYSA-N 3-fluoro-6-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=C(F)C(C(O)=O)=N1 OZSDTKZLTREFCH-UHFFFAOYSA-N 0.000 claims 1
- DDPNELLXOVSMGM-RBUKOAKNSA-N 4-methyl-n-[(1s,5r)-1-(pyridine-2-carbonylamino)-5-bicyclo[3.2.1]octanyl]-1,3-thiazole-2-carboxamide Chemical compound CC1=CSC(C(=O)N[C@@]23C[C@@](CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 DDPNELLXOVSMGM-RBUKOAKNSA-N 0.000 claims 1
- DPOOKUAQJYZPIH-UHFFFAOYSA-N 5-methyl-n-[1-(pyrimidine-4-carbonylamino)-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound C1=NC(C)=CN=C1C(=O)NC1(CCC2)CC2(NC(=O)C=2N=CN=CC=2)CC1 DPOOKUAQJYZPIH-UHFFFAOYSA-N 0.000 claims 1
- OYBQCUZBVHFPBU-UHFFFAOYSA-N 5-methylpyrazine-2-carboxamide Chemical compound CC1=CN=C(C(N)=O)C=N1 OYBQCUZBVHFPBU-UHFFFAOYSA-N 0.000 claims 1
- CWFPGAIJKMNVBI-UXHICEINSA-N 6-methyl-n-[(1r,5s)-1-(pyridine-2-carbonylamino)-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound CC1=CN=CC(C(=O)N[C@]23C[C@](CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 CWFPGAIJKMNVBI-UXHICEINSA-N 0.000 claims 1
- CWFPGAIJKMNVBI-VQTJNVASSA-N 6-methyl-n-[(1s,5r)-1-(pyridine-2-carbonylamino)-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound CC1=CN=CC(C(=O)N[C@@]23C[C@@](CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 CWFPGAIJKMNVBI-VQTJNVASSA-N 0.000 claims 1
- CWFPGAIJKMNVBI-UHFFFAOYSA-N 6-methyl-n-[1-(pyridine-2-carbonylamino)-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound CC1=CN=CC(C(=O)NC23CC(CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 CWFPGAIJKMNVBI-UHFFFAOYSA-N 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 235000002597 Solanum melongena Nutrition 0.000 claims 1
- 244000061458 Solanum melongena Species 0.000 claims 1
- 230000006389 acute stress response Effects 0.000 claims 1
- 230000006978 adaptation Effects 0.000 claims 1
- 208000012826 adjustment disease Diseases 0.000 claims 1
- 208000029650 alcohol withdrawal Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000025307 bipolar depression Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- BCEYKJNPCWQUTL-UXHICEINSA-N n-[(1r,5s)-5-[(6-methylpyridine-2-carbonyl)amino]-1-bicyclo[3.2.1]octanyl]pyrimidine-4-carboxamide Chemical compound CC1=CC=CC(C(=O)N[C@]23C[C@](CC2)(CCC3)NC(=O)C=2N=CN=CC=2)=N1 BCEYKJNPCWQUTL-UXHICEINSA-N 0.000 claims 1
- XURKWFWIYAQJGJ-RBUKOAKNSA-N n-[(1s,5r)-1-[(6-methylpyridine-2-carbonyl)amino]-5-bicyclo[3.2.1]octanyl]-1,3-thiazole-2-carboxamide Chemical compound CC1=CC=CC(C(=O)N[C@]23C[C@](CC2)(CCC3)NC(=O)C=2SC=CN=2)=N1 XURKWFWIYAQJGJ-RBUKOAKNSA-N 0.000 claims 1
- BCEYKJNPCWQUTL-VQTJNVASSA-N n-[(1s,5r)-5-[(6-methylpyridine-2-carbonyl)amino]-1-bicyclo[3.2.1]octanyl]pyrimidine-4-carboxamide Chemical compound CC1=CC=CC(C(=O)N[C@@]23C[C@@](CC2)(CCC3)NC(=O)C=2N=CN=CC=2)=N1 BCEYKJNPCWQUTL-VQTJNVASSA-N 0.000 claims 1
- XIJIWQOWOWSHNN-UHFFFAOYSA-N n-[1-[(4-methylpyridine-2-carbonyl)amino]-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound CC1=CC=NC(C(=O)NC23CC(CC2)(CCC3)NC(=O)C=2N=CC=NC=2)=C1 XIJIWQOWOWSHNN-UHFFFAOYSA-N 0.000 claims 1
- RSWLKNNEKJMTPU-UHFFFAOYSA-N n-[1-[(5-fluoropyridine-2-carbonyl)amino]-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound N1=CC(F)=CC=C1C(=O)NC1(CCC2)CC2(NC(=O)C=2N=CC=NC=2)CC1 RSWLKNNEKJMTPU-UHFFFAOYSA-N 0.000 claims 1
- TVKHKQGELWUTQW-UHFFFAOYSA-N n-[1-[(6-methylpyridin-2-yl)carbamoyl]-5-bicyclo[3.2.1]octanyl]-1,3-thiazole-2-carboxamide Chemical compound CC1=CC=CC(NC(=O)C23CC(CC2)(CCC3)NC(=O)C=2SC=CN=2)=N1 TVKHKQGELWUTQW-UHFFFAOYSA-N 0.000 claims 1
- TYZGEGRPQHQHHB-UHFFFAOYSA-N n-[1-[(6-methylpyridin-2-yl)carbamoyl]-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound CC1=CC=CC(NC(=O)C23CC(CC2)(CCC3)NC(=O)C=2N=CC=NC=2)=N1 TYZGEGRPQHQHHB-UHFFFAOYSA-N 0.000 claims 1
- RIEHSFZHPBDKTM-UHFFFAOYSA-N n-[1-[(6-methylpyridin-2-yl)carbamoyl]-5-bicyclo[3.2.1]octanyl]pyridine-2-carboxamide Chemical compound CC1=CC=CC(NC(=O)C23CC(CC2)(CCC3)NC(=O)C=2N=CC=CC=2)=N1 RIEHSFZHPBDKTM-UHFFFAOYSA-N 0.000 claims 1
- XURKWFWIYAQJGJ-UHFFFAOYSA-N n-[1-[(6-methylpyridine-2-carbonyl)amino]-5-bicyclo[3.2.1]octanyl]-1,3-thiazole-2-carboxamide Chemical compound CC1=CC=CC(C(=O)NC23CC(CC2)(CCC3)NC(=O)C=2SC=CN=2)=N1 XURKWFWIYAQJGJ-UHFFFAOYSA-N 0.000 claims 1
- YMXWZZMWGKZYKO-UHFFFAOYSA-N n-[1-[(6-methylpyridine-2-carbonyl)amino]-5-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound CC1=CC=CC(C(=O)NC23CC(CC2)(CCC3)NC(=O)C=2N=CC=NC=2)=N1 YMXWZZMWGKZYKO-UHFFFAOYSA-N 0.000 claims 1
- AHXCIGWCCCYWLC-UHFFFAOYSA-N n-[1-[(6-methylpyridine-2-carbonyl)amino]-5-bicyclo[3.2.1]octanyl]pyrimidine-2-carboxamide Chemical compound CC1=CC=CC(C(=O)NC23CC(CC2)(CCC3)NC(=O)C=2N=CC=CN=2)=N1 AHXCIGWCCCYWLC-UHFFFAOYSA-N 0.000 claims 1
- YXHWFCJODPXPON-UHFFFAOYSA-N n-[5-[(3-fluoropyridine-2-carbonyl)amino]-1-bicyclo[3.2.1]octanyl]pyrazine-2-carboxamide Chemical compound FC1=CC=CN=C1C(=O)NC1(CCC2)CC2(NC(=O)C=2N=CC=NC=2)CC1 YXHWFCJODPXPON-UHFFFAOYSA-N 0.000 claims 1
- BCEYKJNPCWQUTL-UHFFFAOYSA-N n-[5-[(6-methylpyridine-2-carbonyl)amino]-1-bicyclo[3.2.1]octanyl]pyrimidine-4-carboxamide Chemical compound CC1=CC=CC(C(=O)NC23CC(CC2)(CCC3)NC(=O)C=2N=CN=CC=2)=N1 BCEYKJNPCWQUTL-UHFFFAOYSA-N 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical compound NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 0 *C(NC(CC1)(C2)CCCC12I*)O Chemical compound *C(NC(CC1)(C2)CCCC12I*)O 0.000 description 1
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061426379P | 2010-12-22 | 2010-12-22 | |
| US61/426,379 | 2010-12-22 | ||
| PCT/US2011/066690 WO2012088365A1 (en) | 2010-12-22 | 2011-12-22 | Bicyclo[3.2.1]octyl amide derivatives and uses of same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016041981A Division JP6087006B2 (ja) | 2010-12-22 | 2016-03-04 | ビシクロ［３．２．１］オクチルアミド誘導体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014508128A JP2014508128A (ja) | 2014-04-03 |
| JP2014508128A5 true JP2014508128A5 (cg-RX-API-DMAC7.html) | 2015-02-19 |
| JP5992436B2 JP5992436B2 (ja) | 2016-09-14 |
Family
ID=46314466
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013546401A Expired - Fee Related JP5992436B2 (ja) | 2010-12-22 | 2011-12-22 | ビシクロ［３．２．１］オクチルアミド誘導体およびその使用 |
| JP2016041981A Expired - Fee Related JP6087006B2 (ja) | 2010-12-22 | 2016-03-04 | ビシクロ［３．２．１］オクチルアミド誘導体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016041981A Expired - Fee Related JP6087006B2 (ja) | 2010-12-22 | 2016-03-04 | ビシクロ［３．２．１］オクチルアミド誘導体およびその使用 |
Country Status (30)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ604716A (en) | 2010-07-02 | 2014-12-24 | Gilead Sciences Inc | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| MA34397B1 (fr) | 2010-07-02 | 2013-07-03 | Gilead Sciences Inc | Dérivés d'acide napht-2-ylacétique dans le traitement du sida |
| TWI538905B (zh) * | 2010-12-22 | 2016-06-21 | Ｈ 朗德貝克公司 | 雙環［３．２．１］辛基醯胺衍生物及其用途 |
| AP2013007249A0 (en) | 2011-04-21 | 2013-11-30 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use |
| WO2013040535A2 (en) * | 2011-09-16 | 2013-03-21 | H. Lundbeck A/S | Bicarbocyclic and tricarbocyclic ethynyl derivatives and uses of same |
| WO2013103738A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | Napthalene acetic acid derivatives against hiv infection |
| WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
| SG11201401189WA (en) | 2012-04-20 | 2014-09-26 | Gilead Sciences Inc | Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection |
| US11083725B2 (en) | 2014-10-24 | 2021-08-10 | St. Jude Children's Research Hospital | Coordinated metabolic reprogramming in response to productive viral infections |
| AU2016257302A1 (en) * | 2015-05-05 | 2017-11-16 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives |
| WO2016205304A1 (en) * | 2015-06-16 | 2016-12-22 | Signal Pharmaceuticals, Llc | Methods of treatment using substituted diaminopyrimidyl compounds |
| TW201808914A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TWI844006B (zh) * | 2016-05-05 | 2024-06-01 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808888A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| JP2020522553A (ja) * | 2017-06-07 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ａｔｆ４経路阻害剤としての化合物 |
| JP2020525513A (ja) * | 2017-07-03 | 2020-08-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物 |
| PH12020550028B1 (en) | 2017-08-09 | 2024-05-24 | Denali Therapeutics Inc | Compounds, compositions and methods |
| DK3676297T3 (da) | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| BR112020008817B8 (pt) * | 2017-11-02 | 2023-10-03 | Abbvie Inc | Compostos moduladores da via de estresse integrada |
| AU2018358160B2 (en) | 2017-11-02 | 2023-03-16 | Abbvie Inc. | Modulators of the integrated stress pathway |
| UY37957A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37956A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| US20210130308A1 (en) * | 2018-03-23 | 2021-05-06 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| TWI771621B (zh) | 2018-10-11 | 2022-07-21 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| KR20210126036A (ko) | 2019-02-13 | 2021-10-19 | 데날리 테라퓨틱스 인크. | 화합물, 조성물 및 방법 |
| US12091392B2 (en) | 2019-02-13 | 2024-09-17 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| JP7765386B2 (ja) * | 2019-10-21 | 2025-11-06 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 発達障害の予防、軽減又は治療のためのイミダゾピリミジン又はイミダゾトリアジン化合物の使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204292B1 (en) | 1997-07-18 | 2001-03-20 | Georgetown University | Bicyclic metabotropic glutamate receptor ligands |
| PE20001236A1 (es) * | 1998-11-13 | 2000-11-10 | Lilly Co Eli | Moduladores del receptor de aminoacidos excitadores |
| AU778063C (en) | 1999-06-02 | 2005-12-15 | Astrazeneca Ab | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| JP4815083B2 (ja) * | 1999-08-31 | 2011-11-16 | メルク・シャープ・エンド・ドーム・コーポレイション | 複素環化合物およびそれの使用方法 |
| BR0015545A (pt) * | 1999-11-12 | 2002-08-06 | Biogen Inc | Policicloalquilpurinas como antagonistas dos receptores para adenosina |
| MXPA06000940A (es) | 2003-07-24 | 2006-03-30 | Euro Celtique Sa | Agentes terapeuticos utiles para el tratamiento de dolor. |
| HRP20130968T1 (hr) * | 2008-07-25 | 2013-11-22 | H. Lundbeck A/S | Derivati adamantil diamida i njihova uporaba |
| TWI538905B (zh) * | 2010-12-22 | 2016-06-21 | Ｈ 朗德貝克公司 | 雙環［３．２．１］辛基醯胺衍生物及其用途 |
-
2011
- 2011-12-21 TW TW100147680A patent/TWI538905B/zh not_active IP Right Cessation
- 2011-12-21 AR ARP110104844A patent/AR084457A1/es unknown
- 2011-12-22 CA CA2821937A patent/CA2821937A1/en not_active Abandoned
- 2011-12-22 AP AP2013006984A patent/AP3758A/en active
- 2011-12-22 WO PCT/US2011/066690 patent/WO2012088365A1/en not_active Ceased
- 2011-12-22 EA EA201390908A patent/EA026362B1/ru not_active IP Right Cessation
- 2011-12-22 KR KR1020137016284A patent/KR101840076B1/ko not_active Expired - Fee Related
- 2011-12-22 US US13/334,129 patent/US8921370B2/en not_active Expired - Fee Related
- 2011-12-22 JP JP2013546401A patent/JP5992436B2/ja not_active Expired - Fee Related
- 2011-12-22 NZ NZ612000A patent/NZ612000A/en not_active IP Right Cessation
- 2011-12-22 EP EP11852103.8A patent/EP2654422B1/en active Active
- 2011-12-22 MX MX2013007104A patent/MX2013007104A/es active IP Right Grant
- 2011-12-22 PE PE2013001463A patent/PE20141529A1/es not_active Application Discontinuation
- 2011-12-22 SG SG2013048558A patent/SG191317A1/en unknown
- 2011-12-22 GE GEAP201113166A patent/GEP20156219B/en unknown
- 2011-12-22 NZ NZ705710A patent/NZ705710A/en not_active IP Right Cessation
- 2011-12-22 BR BR112013015592A patent/BR112013015592A8/pt not_active IP Right Cessation
- 2011-12-22 UA UAA201308888A patent/UA109802C2/uk unknown
- 2011-12-22 CN CN201510626898.8A patent/CN105348185B/zh not_active Expired - Fee Related
- 2011-12-22 EP EP17178046.3A patent/EP3263566A1/en not_active Withdrawn
- 2011-12-22 MA MA36100A patent/MA34819B1/fr unknown
- 2011-12-22 CN CN201180067923.3A patent/CN103369961B/zh not_active Expired - Fee Related
- 2011-12-22 MX MX2015011089A patent/MX349132B/es unknown
- 2011-12-22 MY MYPI2013002338A patent/MY169432A/en unknown
- 2011-12-22 AU AU2011348188A patent/AU2011348188B2/en not_active Ceased
-
2012
- 2012-12-22 PH PH1/2013/501340A patent/PH12013501340A1/en unknown
-
2013
- 2013-06-14 TN TNP2013000253A patent/TN2013000253A1/fr unknown
- 2013-06-16 IL IL226981A patent/IL226981A/en not_active IP Right Cessation
- 2013-06-19 DO DO2013000142A patent/DOP2013000142A/es unknown
- 2013-06-20 GT GT201300164A patent/GT201300164A/es unknown
- 2013-06-21 ZA ZA2013/04624A patent/ZA201304624B/en unknown
- 2013-06-21 CR CR20130309A patent/CR20130309A/es unknown
- 2013-07-17 CO CO13169779A patent/CO6741203A2/es unknown
- 2013-07-23 EC ECSP13012788 patent/ECSP13012788A/es unknown
-
2014
- 2014-08-18 ZA ZA2014/06059A patent/ZA201406059B/en unknown
- 2014-11-04 US US14/532,114 patent/US9656975B2/en not_active Expired - Fee Related
-
2016
- 2016-03-04 JP JP2016041981A patent/JP6087006B2/ja not_active Expired - Fee Related
- 2016-05-17 AU AU2016203192A patent/AU2016203192B2/en not_active Expired - Fee Related
-
2017
- 2017-04-18 US US15/489,971 patent/US20170217950A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014508128A5 (cg-RX-API-DMAC7.html) | ||
| RU2454405C2 (ru) | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина | |
| KR102093608B1 (ko) | 이미다조피리딘 화합물 | |
| JP2018522823A5 (cg-RX-API-DMAC7.html) | ||
| JP2007514003A5 (cg-RX-API-DMAC7.html) | ||
| WO2017195216A4 (en) | Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors | |
| JP2017533968A5 (cg-RX-API-DMAC7.html) | ||
| WO2017048962A1 (en) | Hepatitis b core protein modulators | |
| JP2017524005A5 (cg-RX-API-DMAC7.html) | ||
| JP2010540462A5 (cg-RX-API-DMAC7.html) | ||
| RU2013108702A (ru) | Ингибиторы деметилазы lsd1 на основе арилциклопропиламина и их применение в медицине | |
| JP2008513516A5 (cg-RX-API-DMAC7.html) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| RU2017145650A (ru) | Ингибиторы тирозинкиназы брутона | |
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| JP2011509259A5 (cg-RX-API-DMAC7.html) | ||
| IL264982B (en) | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors | |
| JP2018505898A5 (cg-RX-API-DMAC7.html) | ||
| RU2014145856A (ru) | Азотсодержащее гетероциклическое соединение или его соль | |
| NZ705710A (en) | Bicyclo[3.2.1]octyl amide derivatives and uses of same | |
| JP2013535460A5 (cg-RX-API-DMAC7.html) | ||
| CA2482346A1 (en) | Substituted phenylacetamides and their use as glucokinase activators | |
| RU2016134749A (ru) | Гетероциклическое сульфонамидное производное и лекарственное средство, содержащее такое производное | |
| JP2017506237A5 (cg-RX-API-DMAC7.html) | ||
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 |